Company Profile
Rigel Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- RIGL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
39.22 USD (-3.11%)
Close
Last updated: August 6, 2026
555M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, RIGL closed down 3.11% at $39.22. No new same-company headline was identified in the current news window.
Company overview
Hematology and Oncology
Rigel Pharmaceuticals is a commercial-stage biotechnology company focused on hematologic disorders and cancer. It combines a growing portfolio of marketed medicines with internally developed and licensed clinical programs.
TAVALISSE
TAVALISSE, or fostamatinib, is Rigel's therapy for chronic immune thrombocytopenia. It anchors the company's commercial hematology franchise and is sold directly in the United States and through international partners.
GAVRETO and REZLIDHIA
GAVRETO, or pralsetinib, targets RET-altered cancers, while REZLIDHIA, or olutasidenib, treats relapsed or refractory IDH1-mutated acute myeloid leukemia. Together they extend Rigel's commercial presence into precision oncology.
VEPPANU
VEPPANU, or vepdegestrant, is an FDA-approved PROTAC for ESR1-mutated, ER-positive/HER2-negative advanced or metastatic breast cancer. Rigel licensed global development, manufacturing and commercialization rights from Arvinas and Pfizer.
R289
R289 is an oral prodrug of a dual IRAK1/4 inhibitor in Phase 1b development for relapsed or refractory lower-risk myelodysplastic syndrome. The program is evaluating dose expansion and selection of a recommended Phase 2 dose.
Future catalysts
U.S. commercial availability of VEPPANU in mid-August 2026.
Completion of R289 Phase 1b dose-expansion enrollment and selection of a recommended Phase 2 dose in the second half of 2026.
Preliminary R289 dose-expansion data by year-end 2026.
Recent news
- 01
Rigel Reports Second Quarter 2026 Financial Results
Source: Rigel Pharmaceuticals
- 02
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
Source: Rigel Pharmaceuticals
- 03
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
Source: Rigel Pharmaceuticals
- 04
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
Source: Rigel Pharmaceuticals
- 05
Rigel to Present at the Jefferies Global Healthcare Conference
Source: Rigel Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Rigel Pharmaceuticals (RIGL)?
Rigel Pharmaceuticals (RIGL) most recently closed at 39.22 USD, a -3.11% move versus the previous session.
What is the market cap of Rigel Pharmaceuticals (RIGL)?
Rigel Pharmaceuticals currently has a market capitalization of 555M USD on BioPharmSignal.
What does Rigel Pharmaceuticals do?
Hematology and Oncology Rigel Pharmaceuticals is a commercial-stage biotechnology company focused on hematologic disorders and cancer. It combines a growing portfolio of marketed medicines with internally developed and licensed clinical programs. TAVALISSE TAVALISSE, or fostamatinib, is Rigel's therapy for chronic immune thrombocytopenia. It anchors the...
On which exchange is RIGL stock listed?
Rigel Pharmaceuticals (RIGL) is associated with NASDAQ, United States, Biopharma.
What is fostamatinib?
TAVALISSE TAVALISSE, or fostamatinib, is Rigel's therapy for chronic immune thrombocytopenia.
Which conditions is Rigel Pharmaceuticals targeting with fostamatinib?
Rigel Pharmaceuticals is associated with oncology, cancer therapeutics, hematology based on its company overview and current catalyst commentary.
How does Rigel Pharmaceuticals describe recent progress with fostamatinib?
U.S. commercial availability of VEPPANU in mid-August 2026. Completion of R289 Phase 1b dose-expansion enrollment and selection of a recommended Phase 2 dose in the second half of 2026. Preliminary R289 dose-expansion data by year-end 2026.
What is pralsetinib?
GAVRETO and REZLIDHIA GAVRETO, or pralsetinib, targets RET-altered cancers, while REZLIDHIA, or olutasidenib, treats relapsed or refractory IDH1-mutated acute myeloid leukemia.